{"id":"7938bacf328f","type":"article","url":"https://hartvaat.nl/2026/02/05/eenmaal-per-maand-efimosfermine-bij-niet-cirrotische-mash/","title":"Eenmaal per maand efimosfermine bij niet-cirrotische MASH","title_en":"Once-monthly efimosfermin for non-cirrhotic MASH","category":"algemeen","category_label":"Algemeen","professions":["internist"],"tags":[],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02431-6/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02431-6/fulltext","authors":["Luca Valenti","Giulia Periti"],"significance":7,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/kleplijden/aortastenose/"],"congress":"","summary_en":"This Lancet article discussed once-monthly efimosfermin for non-cirrhotic MASH, addressing the growing intersection between metabolic liver disease and cardiovascular risk through a novel FGF21-based therapeutic approach.","created":"2026-07-03T10:25:25Z","updated":"2026-07-03T13:24:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"MASLD is de meest voorkomende leverziekte ter wereld en treft één op de drie mensen. MASH kan progresseren naar leverfibrose en cirrose. Dit commentaar bespreekt het potentieel van maandelijkse efimosfermine bij niet-cirrotische MASH.","abstract_original":"Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the leading cause of liver disease worldwide, affecting one in three people.1,2 The inflammatory form of MASLD, namely metabolic steatohepatitis (MASH), can progress to liver fibrosis and is the most rapidly rising cause of cirrhosis and hepatocellular carcinoma, especially in women.1 In the past 2 years, the THR-β agonist resmetirom and the GLP-1 receptor agonist semaglutide were the first drugs to receive conditional approval for treating non-cirrhotic MASH."}